Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
Identifieur interne : 000790 ( Main/Exploration ); précédent : 000789; suivant : 000791Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
Auteurs : Steven R. Schwid [États-Unis] ; Janice Bausch [États-Unis] ; David Oakes [États-Unis] ; Lynn Schuchter [États-Unis] ; Caroline Tanner [États-Unis] ; Misser Forrest [Danemark] ; Anthony E. Lang [Canada] ; Ira Shoulson [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-09-15.
English descriptors
- KwdEn :
Abstract
We performed a placebo‐controlled trial of CEP‐1347, an inhibitor of neuronal apoptotic cell death, in patients with early Parkinson's disease (PD) to determine whether long‐term therapy would slow disability progression. This also provided an opportunity to monitor cancer incidence in a large cohort of PD patients followed prospectively including periods before and after patients developed disability requiring dopaminergic therapy. This was a multicenter study of 806 patients with early PD, without disability requiring dopaminergic therapy, assigned randomly to placebo or one of three doses of CEP‐1347. Patients were monitored for an average of 1.8 years (1,467 patient‐years) with routine cancer screening evaluations and annual skin examinations by a dermatologist. There was no significant excess of cancers among patients taking CEP‐1347 compared with placebo for any cancer type (all P > 0.1). Nonmelanoma skin cancers were the most common cancer type observed. The incidence of melanomas was 20.9 times that predicted in the general population. Most melanomas occurred in patients who had never taken dopaminergic therapy. We found no evidence that CEP‐1347 affected cancer incidence within 2 years of follow‐up. Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23006
Affiliations:
- Canada, Danemark, États-Unis
- Californie, Hovedstaden, Ontario, Pennsylvanie, État de New York
- Copenhague
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease</title><author><name sortKey="Schwid, Steven R" sort="Schwid, Steven R" uniqKey="Schwid S" first="Steven R." last="Schwid">Steven R. Schwid</name></author><author><name sortKey="Bausch, Janice" sort="Bausch, Janice" uniqKey="Bausch J" first="Janice" last="Bausch">Janice Bausch</name></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name></author><author><name sortKey="Schuchter, Lynn" sort="Schuchter, Lynn" uniqKey="Schuchter L" first="Lynn" last="Schuchter">Lynn Schuchter</name></author><author><name sortKey="Tanner, Caroline" sort="Tanner, Caroline" uniqKey="Tanner C" first="Caroline" last="Tanner">Caroline Tanner</name></author><author><name sortKey="Forrest, Misser" sort="Forrest, Misser" uniqKey="Forrest M" first="Misser" last="Forrest">Misser Forrest</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23006</idno><idno type="url">https://api.istex.fr/document/289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000306</idno><idno type="wicri:Area/Main/Curation">000259</idno><idno type="wicri:Area/Main/Exploration">000790</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease</title><author><name sortKey="Schwid, Steven R" sort="Schwid, Steven R" uniqKey="Schwid S" first="Steven R." last="Schwid">Steven R. Schwid</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Neurology, University of Rochester, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Bausch, Janice" sort="Bausch, Janice" uniqKey="Bausch J" first="Janice" last="Bausch">Janice Bausch</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Biostatistics and Computational Biology, University of Rochester, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Biostatistics and Computational Biology, University of Rochester, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Schuchter, Lynn" sort="Schuchter, Lynn" uniqKey="Schuchter L" first="Lynn" last="Schuchter">Lynn Schuchter</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Medicine, University of Pennsylvania, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="Tanner, Caroline" sort="Tanner, Caroline" uniqKey="Tanner C" first="Caroline" last="Tanner">Caroline Tanner</name><affiliation wicri:level="2"><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Department of Clinical Research, Parkinson's Institute, Sunnyvale</wicri:cityArea></affiliation></author><author><name sortKey="Forrest, Misser" sort="Forrest, Misser" uniqKey="Forrest M" first="Misser" last="Forrest">Misser Forrest</name><affiliation wicri:level="3"><country xml:lang="fr">Danemark</country><wicri:regionArea>H. Lundbeck A/S, Copenhagen</wicri:regionArea><placeName><settlement type="city">Copenhague</settlement><region type="région" nuts="2">Hovedstaden</region></placeName></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="2"><country>Canada</country><placeName><region type="province">Ontario</region></placeName><wicri:cityArea>Division of Neurology, Toronto Western Hospital, Toronto</wicri:cityArea></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Neurology, University of Rochester, Rochester</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-09-15">2010-09-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1801">1801</biblScope><biblScope unit="page" to="1808">1808</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF</idno><idno type="DOI">10.1002/mds.23006</idno><idno type="ArticleID">MDS23006</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>L‐dopa</term><term>Melanoma</term><term>Parkinson's disease</term><term>apoptosis</term><term>cancer</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We performed a placebo‐controlled trial of CEP‐1347, an inhibitor of neuronal apoptotic cell death, in patients with early Parkinson's disease (PD) to determine whether long‐term therapy would slow disability progression. This also provided an opportunity to monitor cancer incidence in a large cohort of PD patients followed prospectively including periods before and after patients developed disability requiring dopaminergic therapy. This was a multicenter study of 806 patients with early PD, without disability requiring dopaminergic therapy, assigned randomly to placebo or one of three doses of CEP‐1347. Patients were monitored for an average of 1.8 years (1,467 patient‐years) with routine cancer screening evaluations and annual skin examinations by a dermatologist. There was no significant excess of cancers among patients taking CEP‐1347 compared with placebo for any cancer type (all P > 0.1). Nonmelanoma skin cancers were the most common cancer type observed. The incidence of melanomas was 20.9 times that predicted in the general population. Most melanomas occurred in patients who had never taken dopaminergic therapy. We found no evidence that CEP‐1347 affected cancer incidence within 2 years of follow‐up. Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted. © 2010 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Canada</li><li>Danemark</li><li>États-Unis</li></country><region><li>Californie</li><li>Hovedstaden</li><li>Ontario</li><li>Pennsylvanie</li><li>État de New York</li></region><settlement><li>Copenhague</li></settlement></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Schwid, Steven R" sort="Schwid, Steven R" uniqKey="Schwid S" first="Steven R." last="Schwid">Steven R. Schwid</name></region><name sortKey="Bausch, Janice" sort="Bausch, Janice" uniqKey="Bausch J" first="Janice" last="Bausch">Janice Bausch</name><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name><name sortKey="Schuchter, Lynn" sort="Schuchter, Lynn" uniqKey="Schuchter L" first="Lynn" last="Schuchter">Lynn Schuchter</name><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><name sortKey="Tanner, Caroline" sort="Tanner, Caroline" uniqKey="Tanner C" first="Caroline" last="Tanner">Caroline Tanner</name></country><country name="Danemark"><region name="Hovedstaden"><name sortKey="Forrest, Misser" sort="Forrest, Misser" uniqKey="Forrest M" first="Misser" last="Forrest">Misser Forrest</name></region></country><country name="Canada"><region name="Ontario"><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000790 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000790 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF
|texte= Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |